Alexandria Real Estate Equities, Inc. research snapshot
ARE AI stock analysis currently reads Alexandria Real Estate Equities as a specialized life science REIT with scarce cluster assets but an unfinished balance sheet repair story. At the August 2, 2026 cutoff, ARE closed at $51.45 on July 31, 2026, market capitalization was about $8.97 billion, and the stock traded near 0.56x book value. The quarterly dividend was reset to $0.72 per share from $1.32, which cuts the forward yield to roughly 5.6% instead of the misleading trailing 9.1%. The AI stock forecast is scenario-based because 2026 adjusted FFO guidance of $6.30 to $6.50 per share is the more useful anchor than GAAP earnings, which are distorted by impairments and a $1.33 billion debt tender gain. This page is informational research and not investment advice.
Current price
$51.45
Market cap
$8.97 billion
AI score
54 / 100
Rating
High-quality life science REIT still de-risking after a dividend reset
Trend status
Above the 50-day average, just below the 200-day average
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | ARE owns scarce laboratory and life science campuses in AAA innovation clusters including Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, and Research Triangle. The assets are hard to replicate, but 1Q26 average occupancy fell to 88.9% from 94.0% a year earlier, which shows demand is cyclical. | Medium-high |
| Moat | The moat comes from cluster location, lab-ready infrastructure, tenant relationships, scale, zoning scarcity, and operating know-how. It does not shield ARE from tenant funding cycles, 2026 key lease expirations, or competing sublease supply. | Medium |
| Management | Management is executing a de-risking plan: a dividend reset, a $1.33 billion debt tender, repayment of 2026 maturities, reduced capital spend, and $2.1 billion to $3.7 billion of planned dispositions. The test is whether this lowers leverage toward the 5.6x to 6.2x target without permanently damaging earnings power. | Medium |
| Financial trend | TTM revenue through March 2026 was $2.93 billion, down from $3.03 billion in FY2025, and TTM common stockholder net loss was about $1.07 billion. Q1 2026 adjusted FFO per share was $1.73, and 2026 adjusted FFO guidance is $6.30 to $6.50 per share. | High |
| Valuation | At $51.45, ARE traded near 0.56x book value and at roughly 8.0x forward adjusted FFO using the $6.40 guidance midpoint. The trailing P/FFO of 5.26x is flattered by pre-disposition 2025 FFO. The discount is real, but it prices ongoing occupancy, leverage, and dividend risk. | Medium-high |
| Technical trend | ARE closed above its 50-day moving average of $50.88 and just below its 200-day moving average of $51.77, so the chart shows a short-term recovery that has not yet confirmed a repaired longer-term trend. | Medium |
| Risk level | Risk is elevated for a REIT: net debt plus preferred stock to adjusted EBITDA was 6.8x in 1Q26 annualized, revenue is expected to fall again in 2026, occupancy guidance embeds a benefit assumption from potential asset sales, and the dividend has already been cut once. | Medium-high |
| AI confidence | High for price, share count, filings, 2025 and TTM financials, Q1 2026 operating data, 2026 guidance, and technical inputs; medium for leasing recovery timing, disposition pricing, and private life science funding conditions. | High data confidence |
| Investment certainty | Medium-low certainty. The asset base is high quality, but the margin of safety depends on a visible operating recovery and sustained deleveraging, not just a low book multiple. | Medium-low |
ARE AI stock forecast
The ARE AI stock forecast uses adjusted FFO, book value, occupancy, and leverage rather than GAAP EPS alone. The bullish case requires evidence that occupancy stabilizes, the 1.1 million RSF of leased but undelivered space converts to revenue in 2H26, dispositions close near guidance pricing, and net debt to adjusted EBITDA reaches the 5.6x to 6.2x target. The bearish case becomes more likely if 2026 occupancy or same-property NOI weakens again, disposition pricing is weak, or 2027 occupancy faces the headwinds that some analysts now flag.
$58 to $65
More likely if ARE stabilizes operating occupancy, delivers the 1.1 million RSF of leased space into revenue around September 2026, completes dispositions near the $2.9 billion guidance midpoint, and reduces net debt leverage while holding the $0.72 dividend. The verified three-scenario model produced about $61 using 4% annual adjusted FFO growth and an 8x terminal multiple.
$47 to $54
More likely if ARE remains a repair story: adjusted FFO holds near the $6.40 guidance midpoint, occupancy stops falling but recovery is slow, the 200-day moving average stays as overhead resistance, and the market waits for 2H26 same-property improvement. The model base case was about $49.50.
$25 to $33
More likely if tenant demand weakens further, 2026 occupancy guidance is cut again, dispositions require larger discounts, debt costs stay high, or the dividend is reduced a second time. The verified bear model produced about $27 using lower adjusted FFO and a 5.5x multiple.
ARE AI technical analysis
ARE AI technical analysis starts from the $51.45 close on July 31, 2026. The stock is above its 50-day moving average of $50.88 but below its 200-day moving average of $51.77, so the chart shows a short-term bounce that has not yet cleared the longer-term trend line. Levels should be rechecked around the August 3, 2026 earnings report, REIT rates, dividend news, and leasing disclosures.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $51.45 | Latest verified close used for this page, reported for July 31, 2026. |
| Near support | $50.88 | The 50-day moving average is the first support reference. Holding above it keeps the short-term rebound setup intact. |
| Secondary support | $46 to $48 | Recent 2026 trading zones and analyst low targets sit in this range. A break below would test the 52-week low near $39.41. |
| Near resistance | $52 to $54 | The 200-day moving average at $51.77, recent congestion, and targets such as BMO at $54 create the first meaningful overhead zone. |
| 200-day moving average | $51.77 | A sustained close above the 200-day average would be the first technical sign that longer-term trend damage is improving. |
| Momentum | RSI 52.14 | RSI is neutral, slightly tilted toward recovery. It is not stretched in either direction. |
| Volume | 20-day average 1.51 million shares | Volume expansion around earnings, dispositions, or dividend announcements should be checked for institutional repositioning. |
| Volatility | Beta 1.18 | ARE remains more volatile than the broad market, which is unusual for a defensive REIT label and reflects the current repair phase. |
| Invalidation | Close below $50 or guidance cut | A decisive close below the 50-day average after the August 3 earnings report, a lower occupancy guide, or weaker disposition pricing would weaken the base case. |
ARE AI trading strategy
The ARE AI trading strategy is a rules-based REIT turnaround framework, not personalized advice. Monitor live price, interest rates, the August 3, 2026 earnings report, occupancy, same-property NOI, dividend coverage, disposition proceeds, liquidity, and 2H26 same-property improvement.
Wait for price to hold above the 50-day moving average and clear the 200-day moving average while company updates confirm stable occupancy, positive 2H26 same-property trends, and no further guidance cut.
Reduce confidence if price fails below $50, adjusted FFO guidance declines, or ARE needs larger asset sales at weak pricing.
Use the discount to book value and the reset dividend as a watchlist input only when paired with evidence that occupancy is stabilizing and leverage is tracking toward the 5.6x to 6.2x target.
Do not treat the low price-to-book ratio as a floor. Impairments and further vacancy can keep book value and FFO moving lower.
Track the $0.72 quarterly dividend, common dividends paid, adjusted FFO, operating cash flow retained for reinvestment, debt maturities, disposition proceeds, liquidity, and 4Q26 credit metrics.
A second dividend reset, weaker liquidity, rising debt costs, or missed disposition guidance can override a bullish chart setup.
Investment research summary
Alexandria is paid to provide specialized lab, office, and campus infrastructure to pharmaceutical, biotechnology, biomedical, technology, and institutional tenants. Customers pay for location, lab readiness, ecosystem access, and operational reliability across AAA life science clusters.
The moat is strongest in scarce lab-ready assets in Greater Boston, San Francisco Bay Area, San Diego, Seattle, Maryland, and Research Triangle. It comes from tenant relationships, campus density, real estate execution, and scale. The moat narrows when tenant funding, vacancy, or capital costs dominate the cycle.
The thesis can fail if lab demand stays weak, tenants downsize, occupancy falls below guidance, same-property NOI declines further, asset sales close at poor values, debt markets tighten, or the dividend consumes too much of adjusted FFO. Morgan Stanley now warns that 2027 occupancy may face additional headwinds.
Management has moved decisively to a balance sheet repair mode: cutting the dividend to $0.72, tendering $1.33 billion of debt, repaying 2026 maturities, slowing construction, and planning $2.1 billion to $3.7 billion of dispositions. The key test is whether these moves cut leverage without permanently shrinking earnings power.
The long-term need for life science research infrastructure remains real, but the near-term cycle depends on biotech funding, pharma budgets, rate levels, and tenant utilization. 2026 revenue is still expected to decline about 13% to 14%, and a durable recovery may only become visible in 2H26 and 2027.
The verified model produced about $61 in the bull case, $49.50 in the base case, and $27 in the bear case using adjusted FFO scenarios from the $6.40 guidance midpoint. The margin of safety is conditional on operating stabilization and deleveraging, not only on a low book multiple.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| ARE price | $51.45 close on July 31, 2026 | StockAnalysis overview page | August 2, 2026 |
| Market capitalization | $8.97 billion, verified as $51.45 x 174.27 million shares | financial_rigor.py market cap verification | August 2, 2026 |
| Shares outstanding | 174.27 million | StockAnalysis statistics page | August 2, 2026 |
| TTM revenue | $2.93 billion for the twelve months ended March 31, 2026 | StockAnalysis financials page | August 2, 2026 |
| 2025 net loss | Common stockholder net loss of $1.217 billion for FY2025; TTM common stockholder net loss of about $1.07 billion as of March 31, 2026 | Macrotrends net income page | August 2, 2026 |
| Q1 2026 adjusted FFO per share | $1.73 per diluted share, with $295.9 million of adjusted FFO | ARE 1Q26 results release | August 2, 2026 |
| Q1 2026 occupancy | 88.9% average occupancy, down from 94.0% in the same prior-year period | ARE 1Q26 results release | August 2, 2026 |
| 2026 adjusted FFO guidance | $6.30 to $6.50 per diluted share, midpoint $6.40 | ARE 1Q26 results release | August 2, 2026 |
| Credit and liquidity | Net debt plus preferred stock to adjusted EBITDA of 6.8x for 1Q26 annualized, 4Q26 target 5.6x to 6.2x; liquidity of $4.17 billion, 10.0-year weighted-average debt term | ARE 1Q26 results release | August 2, 2026 |
| Dividend | $0.72 per common share quarterly for 1Q26 and 2Q26, reset from $1.32; annualized $2.88 implies about a 5.6% forward yield at $51.45 | StockAnalysis dividend page and ARE releases | August 2, 2026 |
| Technical indicators | 50-day MA $50.88, 200-day MA $51.77, RSI 52.14, 20-day average volume 1.51 million, beta 1.18 | StockAnalysis statistics page | August 2, 2026 |
| Analyst consensus | Hold consensus from 16 analysts, average price target $51.00, range $42 to $60 | StockAnalysis forecast page | August 2, 2026 |
This ARE AI stock analysis page is an informational tool only and is not investment advice, tax advice, or a recommendation to buy or sell any security. Forecast ranges are scenarios based on available public data as of August 2, 2026 and may be wrong if financial results, rates, tenant demand, asset values, disposition pricing, or market conditions change.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
